Myklebost group becomes part of European Network of Excellence
EU FP6 grant awarded to Bone Tumour Network
Twenty-five European groups have joined forces to make a Network of Excellence that has been funded by the EU FP6 program. The Norwegian Radium Hospital will be responsible for a work package on Biology and Genetics of Osteosarcoma. Our participation is based on, and will strengthen, the National Sarcoma Competence Center at Dnr
European Network to Promote Research into Uncommon Cancers in Adults and Children: Pathology, Biology and Genetics of Bone Tumours "EuroBoNet"
Research topic addressed
– Establishing facilities and developing initiatives for the exploitation of research on cancer in Europe; encouraging the development of evidence based guidelines for good clinical practice and improved public health strategies by accelerating the translation of existing research results into applications.
– Supporting translational research aimed at bringing basic knowledge through to applications in clinical practice and public health.
Proposal abstract
Leading trans European research groups will integrate expertise to increase and disseminate knowledge of primary bone tumours at the molecular level for development of new tools for patient care and cure. Primary bone tumours are rare, accounting ~0.2% of the cancer burden. Children and young adolescents are frequently affected. Their aggressiveness has major impact on morbidity and mortality. Though progress has been made in pathological and genetic typing, the aetiology is largely unknown. Advances in therapeutic approaches increased survival. Significant numbers of patients (~40%) still die from disease. Within a network of experts an exchange of material, knowledge and technology is achieved to obtain statistical significant datasets, otherwise not achievable due to the rareness and the large number of sub entities (the 2002 WHO classification recognises 31 different bone tumours. A joint programme will contribute in obtaining molecular portraits of tumours. We focus on the molecular level, which is expedient since the availability of the wealth of information from the Human Genome Project. Several bone tumours occur within a hereditary syndrome, underpinning importance of combining a tumour and clinical genetic approach. Most tumours yield a complex and as yet not tumour-specific genetic make-up. Some specific genetic events are reported, but this knowledge is not transcribed into comprehensive understanding, nor does it give an anchoring point for designing tumour specific therapy. The WHO has proclaimed (endorsed by EC member countries) the “Bone and Joint Decade”, to improve the health-related quality of life for patients with skeletal disorders. It aims to advance understanding through research improving prevention and treatment. This is optimal done in a multi-institutional network of expertise. Patients usually do not present themselves at centres, which necessitates spreading of knowledge from the network into the community via a joint training program.
Research topic addressed
– Establishing facilities and developing initiatives for the exploitation of research on cancer in Europe; encouraging the development of evidence based guidelines for good clinical practice and improved public health strategies by accelerating the translation of existing research results into applications.
– Supporting translational research aimed at bringing basic knowledge through to applications in clinical practice and public health.
Proposal abstract
Leading trans European research groups will integrate expertise to increase and disseminate knowledge of primary bone tumours at the molecular level for development of new tools for patient care and cure. Primary bone tumours are rare, accounting ~0.2% of the cancer burden. Children and young adolescents are frequently affected. Their aggressiveness has major impact on morbidity and mortality. Though progress has been made in pathological and genetic typing, the aetiology is largely unknown. Advances in therapeutic approaches increased survival. Significant numbers of patients (~40%) still die from disease. Within a network of experts an exchange of material, knowledge and technology is achieved to obtain statistical significant datasets, otherwise not achievable due to the rareness and the large number of sub entities (the 2002 WHO classification recognises 31 different bone tumours. A joint programme will contribute in obtaining molecular portraits of tumours. We focus on the molecular level, which is expedient since the availability of the wealth of information from the Human Genome Project. Several bone tumours occur within a hereditary syndrome, underpinning importance of combining a tumour and clinical genetic approach. Most tumours yield a complex and as yet not tumour-specific genetic make-up. Some specific genetic events are reported, but this knowledge is not transcribed into comprehensive understanding, nor does it give an anchoring point for designing tumour specific therapy. The WHO has proclaimed (endorsed by EC member countries) the “Bone and Joint Decade”, to improve the health-related quality of life for patients with skeletal disorders. It aims to advance understanding through research improving prevention and treatment. This is optimal done in a multi-institutional network of expertise. Patients usually do not present themselves at centres, which necessitates spreading of knowledge from the network into the community via a joint training program.
Go back
Print this page
E-mail this page
